| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8831913 | International Journal of Surgery | 2018 | 9 Pages |
Abstract
Adjuvant systemic chemotherapy is associated with survival benefit in patients with T2 or greater GBCA with node positive disease. We recommend a multidisciplinary approach in these patients as less than 1-in-4 of them currently receive adjuvant chemotherapy. Future clinical trials should address adjuvant chemotherapy in node positive GBCA.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
John R. Bergquist, Harsh N. Shah, Elizabeth B. Habermann, Matthew C. Hernandez, Tommy Ivanics, Michael L. Kendrick, Rory L. Smoot, David M. Nagorney, Mitesh J. Borad, Robert R. McWilliams, Mark J. Truty,